These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 20806117

  • 1. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
    Becker RC, Alexander JH, Newby LK, Yang H, Barrett Y, Mohan P, Wang J, Harrington RA, Wallentin LC.
    Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
    [Abstract] [Full Text] [Related]

  • 2. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    APPRAISE Steering Committee and InvestigatorsDuke Clinical Research Institute, Duke University Medical Center, DUMC Box 3850, Durham, NC 27715, USA. john.h.alexander@duke.edu, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L.
    Circulation; 2009 Jun 09; 119(22):2877-85. PubMed ID: 19470889
    [Abstract] [Full Text] [Related]

  • 3. Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis.
    Barrett YC, Wang J, Knabb R, Mohan P.
    Thromb Haemost; 2011 Jan 09; 105(1):181-9. PubMed ID: 20941459
    [Abstract] [Full Text] [Related]

  • 4. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.
    Barrett YC, Wang J, Song Y, Pursley J, Wastall P, Wright R, Lacreta F, Frost C.
    Thromb Haemost; 2012 May 09; 107(5):916-24. PubMed ID: 22398784
    [Abstract] [Full Text] [Related]

  • 5. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J, Johnston N, Siegbahn A.
    Am Heart J; 2008 Mar 09; 155(3):493.e1-8. PubMed ID: 18294482
    [Abstract] [Full Text] [Related]

  • 6. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro.
    Jiang X, Crain EJ, Luettgen JM, Schumacher WA, Wong PC.
    Thromb Haemost; 2009 Apr 09; 101(4):780-2. PubMed ID: 19350128
    [No Abstract] [Full Text] [Related]

  • 7. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC, Wang Z, Frost C, Shenker A.
    Thromb Haemost; 2010 Dec 09; 104(6):1263-71. PubMed ID: 20978714
    [Abstract] [Full Text] [Related]

  • 8. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
    Zafar MU, Farkouh ME, Osende J, Shimbo D, Palencia S, Crook J, Leadley R, Fuster V, Chesebro JH.
    Thromb Haemost; 2007 Mar 09; 97(3):487-92. PubMed ID: 17334518
    [Abstract] [Full Text] [Related]

  • 9. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P, Kuitunen A, Petäjä J, Ilveskero S, Lassila R.
    Thromb Haemost; 2008 Feb 09; 99(2):427-34. PubMed ID: 18278195
    [Abstract] [Full Text] [Related]

  • 10. Apixaban in acute coronary syndromes.
    Karthikeyan G, Eikelboom JW.
    Cardiovasc Ther; 2011 Oct 09; 29(5):285-90. PubMed ID: 20553278
    [Abstract] [Full Text] [Related]

  • 11. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E.
    Thromb Haemost; 2010 Apr 09; 103(4):815-25. PubMed ID: 20135059
    [Abstract] [Full Text] [Related]

  • 12. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
    Song Y, Wang Z, Perlstein I, Wang J, LaCreta F, Frost RJA, Frost C.
    J Thromb Haemost; 2017 Nov 09; 15(11):2125-2137. PubMed ID: 28846831
    [Abstract] [Full Text] [Related]

  • 13. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.
    Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, Yu Z, Shenker A, Barrett YC, Mosqueda-Garcia R, Lacreta F.
    Br J Clin Pharmacol; 2013 Nov 09; 76(5):776-86. PubMed ID: 23451769
    [Abstract] [Full Text] [Related]

  • 14. Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial.
    Christersson C, Oldgren J, Bylock A, Siegbahn A, Wallentin L.
    Eur Heart J; 2007 Mar 09; 28(6):692-8. PubMed ID: 17314111
    [Abstract] [Full Text] [Related]

  • 15. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers.
    Spiller HA, Mowry JB, Aleguas A, Griffith JR, Goetz R, Ryan ML, Bangh S, Klein-Schwartz W, Schaeffer S, Casavant MJ.
    Ann Emerg Med; 2016 Feb 09; 67(2):189-95. PubMed ID: 26298448
    [Abstract] [Full Text] [Related]

  • 16. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
    Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G.
    Clin Pharmacol Ther; 2005 Oct 09; 78(4):412-21. PubMed ID: 16198660
    [Abstract] [Full Text] [Related]

  • 17. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
    Kreutz R, Persson PB, Kubitza D, Thelen K, Heitmeier S, Schwers S, Becka M, Hemmrich M.
    J Thromb Haemost; 2017 Oct 09; 15(10):2017-2028. PubMed ID: 28805299
    [Abstract] [Full Text] [Related]

  • 18. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
    Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S, Siguret V, Lecompte T.
    Thromb Haemost; 2014 Feb 09; 111(2):240-8. PubMed ID: 24172843
    [Abstract] [Full Text] [Related]

  • 19. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.
    Cheung YW, Barco S, Hutten BA, Meijers JC, Middeldorp S, Coppens M.
    J Thromb Haemost; 2015 Oct 09; 13(10):1799-805. PubMed ID: 26270625
    [Abstract] [Full Text] [Related]

  • 20. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
    Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA.
    N Engl J Med; 2015 Dec 17; 373(25):2413-24. PubMed ID: 26559317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.